Do You Need the Pneumonia Vaccine?

Three FDA-Approved Vaccines for Children and Adults

Pneumonia causes tens of thousands of deaths in the U.S. every year. According to the Centers for Disease Control and Prevention (CDC), over 40,000 people died from Pneumonia in 2021. In addition, the CDC states that 1.5 million people went to emergency departments for pneumonia in 2020.

A study published in 2022 showed the use of pneumonia vaccines is associated with a 24% decreased risk of death. With that being said, rates of vaccinations aren't all that high. Only 67.5% of adults over the age of 65 are vaccinated against pneumonia, and just 24% of younger people (19-64 years old) at risk for pneumonia are vaccinated.

In many cases, people are unsure whether they need the vaccine or which type of pneumonia it is meant to prevent. Others are not even aware a vaccine exists.

2:29

How Pneumonia Occurs

Types of Pneumonia

Pneumonia is defined as the inflammation of the air sacs of the lungs which can fill with fluid and lead to breathing difficulty, fever, chills, and coughing with pus or phlegm. Pneumonia is most commonly caused by germs but can also develop if you inhale food or liquid into the lungs (aspiration pneumonia) or pick up a drug-resistant bacteria while in the hospital (hospital-acquired pneumonia).

The most common type is known as community-acquired pneumonia in which a contagion such as a bacteria, virus, or fungi is spread outside of a healthcare setting. Of these, bacteria is by far the most common cause.

Bacterial pneumonia is typically spread by respiratory droplets that are aerosolized once a person coughs or sneezes. The majority are caused by Streptococcus pneumoniae, a bacterium with more than 90 different serotypes. Of these, 10 types are responsible for the majority of pneumonia-related complications.

While bacterial pneumonia primarily affects the respiratory tract, it can cause serious illness if it spreads into the bloodstream. If this happens, it can infect the blood (pneumococcal bacteremia/sepsis) and cause inflammation of the membranes surrounding the brain and spinal cord (pneumococcal meningitis). The risk of death in people with invasive pneumonia is between 13% to 21%, with older persons being at the higher risk.

Types of Pneumonia Vaccine

Three vaccines can provide protection against Streptococcus pneumoniae. They cannot prevent other types of bacterial pneumonia (such as those caused by Chlamydophila pneumoniae or Mycoplasma pneumoniae) or any associated with a fungus or virus.

These FDA-approved vaccines immunize a person against the specific serotypes that are most likely to cause illness and invasive disease:

  • PCV15 (Vaxneuvance) protects against 15 S. pneumoniae serotypes
  • PCV20 (Prevnar 20) helps prevent infection caused by 20 of the most severe types of S. pneumoniae
  • PPSV23 (Pneumovax 23) protects against 23 S. pneumoniae serotypes

None of these vaccines is made from a live or whole bacteria but rather parts of the bacterial shell. While these components cannot cause disease, the immune system recognizes them as threats and triggers a defensive response in the same way it would to a real bacteria.

The PCV15 and PCV20 vaccines are delivered intramuscularly either into the deltoid muscle of the upper arm or the vastus lateralis muscle of the external thigh. The PPSV23 shot can either be given intramuscularly or subcutaneously (into the skin).

Who Needs Vaccination?

Pneumonia vaccination is not recommended for everyone. The vaccines are primarily used in persons who are at increased risk of serious illness. These include:

  • Infants and children as part of their routine vaccination schedule
  • Persons over the age of 65
  • Persons with compromised or weakened immune systems, including those with chronic illness such as HIV, heart disease, liver disease, kidney failure, and diabetes
  • Organ transplant recipients and person undergoing chemotherapy, both of whom have weakened immune systems and exposure to immune suppressive drugs
  • Persons with chronic respiratory illnesses such as asthma, emphysema, chronic obstructive pulmonary disease (COPD)
  • Persons who smoke (who have an underlying risk of lung infection) or are heavy drinkers (who are more likely to have a suppressed immune system)

Vaccination is currently not recommended for persons between 18 and 64 who are healthy. The same applies to anyone who has had a prior allergic reaction to the vaccine or has a known allergy to any of the components of the vaccine.

Vaccination Recommendations

Pneumonia vaccination is a routine part of a child's immunization schedule. Here are recommendations for which vaccines should be given to which populations, according to the CDC:

PCV15 (Vaxneuvance) or PCV20 (Prevnar 20) is recommended for:

  • Children younger than 2 years old
  • Children ages 2 to 18 years with certain medical conditions
  • Adults 65 years or older
  • Adults ages 19 to 64 years with certain risk factors or medical conditions

PPSV23 (Pneumovax23) is recommended for:

  • Children ages 2 to 18 years with certain medical conditions
  • Adults 19 years and older who get the PCV15 vaccine

If used as recommended, the vaccines should afford you lifetime protection.

Side Effects

Side effects of these vaccines tend to be mild and resolve on their own within one or several days. Most are related to injection site discomfort or manifest with mild, flu-like symptoms. Among the most common symptoms:

  • Fatigue
  • Headaches
  • Low-grade fever
  • Muscle pain (myalgia)
  • Joint pain (arthralgia)
  • Injection site pain, redness, swelling, or tenderness
  • Chills

Less commonly, diarrhea, vomiting, or a skin rash can occur.

In the event of a more severe reaction—including hives, blisters, breathing restriction, facial swelling, tongue swelling, confusion, or seizure—call 911 or go to your nearest emergency room immediately. While rare, an all-body allergic reaction (anaphylaxis) can occur which, if left untreated, can lead to shock, coma, and even death.

13 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. Centers for Disease Control and Prevention. Pneumonia.

  2. Jaiswal V, Ang SP, Lnu K, et al. Effect of Pneumococcal Vaccine on Mortality and Cardiovascular Outcomes: A Systematic Review and Meta-AnalysisJ Clin Med. 2022;11(13):3799. doi:10.3390/jcm11133799

  3. Centers for Disease Control and Prevention. Vaccination Coverage among Adults in the United States, National Health Interview Survey, 2019–2020.

  4. American Lung Association. What Causes Pneumonia?

  5. Loughran AJ, Orihuela CJ, Tuomanen EI. Streptococcus pneumoniae: Invasion and Inflammation. Microbiol Spectr. 2019;7(2). doi:10.1128/microbiolspec.GPP3-0004-2018

  6. Versluys KA, Eurich DT, Marrie TJ, et al. Invasive Pneumococcal Disease and Long-Term Mortality Rates in Adults, Alberta, CanadaEmerging Infectious Diseases. 2022;28(8):1615-1623. doi:10.3201/eid2808.212469.

  7. Centers for Disease Control and Prevention. About pneumococcal vaccines.

  8. Green C, Moore CA, Mahajan A, Bajaj K. A simple approach to pneumococcal vaccination in adults. J Glob Infect Dis. 2018;10(3):159-162. doi:10.4103/jgid.jgid_88_17

  9. Centers for Disease Control and Prevention. Pneumococcal vaccination: summary of who and when to vaccinate.

  10. Torres A, Blasi F, Dartois N, Akova M. Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease. Thorax. 2015;70(10):984-9. doi:10.1136/thoraxjnl-2015-206780

  11. Centers for Disease Control and Prevention. Immunization schedules.

  12. Centers for Disease Control and Prevention. Pneumococcal vaccination: What everyone should know.

  13. Von elten KA, Duran LL, Banks TA, Banks TA, Collins LC, Collins LC. Systemic inflammatory reaction after pneumococcal vaccine: a case series. Hum Vaccin Immunother. 2014;10(6):1767-70. doi:10.4161/hv.28559

Additional Reading

By James Myhre & Dennis Sifris, MD
Dennis Sifris, MD, is an HIV specialist and Medical Director of LifeSense Disease Management. James Myhre is an American journalist and HIV educator.